Biotechnology company Nucleome Therapeutics has signed for 20,000 sq ft of fitted lab and office space at Mission Street and BGO’s Inventa scheme in Oxford.
Nucleome is relocating from its existing headquarters at Oxford Science Park to the 65,000 sq ft building, which is located in Oxford’s West End within walking distance of Oxford train station and the city centre.
In December last year, Mission Street secured planning consent for the second phase of the West End development known as Fabrica, with construction of the 183,000 sq ft scheme due to commence in September.
Artem Korolev, founder and CEO of Mission Street, said: “Following extensive collaboration between our teams in designing and delivering Nucleome’s facility, we are excited to welcome them to Inventa for the next chapter of their growth. We look forward to building a long-term partnership with them and delivering a world class urban innovation district across Inventa, Fabrica and the wider West End.”
Stephen Harrison, chief scientific officer of Nucleome Therapeutics, added: “Nucleome’s expansion, driven by the significant progress in identifying new drug candidates, has resulted in a need for larger office and lab space. We chose Inventa because of its central location, and Mission Street’s reputation for designing buildings that thoroughly accommodate the needs of life science companies. We are looking forward to being part of this exciting new science and innovation hub in central Oxford.”
CBRE and Bidwells advised on the letting.
